Navigation Links
COPD Tops Asthma as the Focus Indication for Next Generation Respiratory Therapies at the 2012 American Thoracic Society Conference
Date:5/31/2012

NEW YORK, May 31, 2012 /PRNewswire/ -- Citeline, the world's leading research authority on pharmaceutical clinical trials, updates, and intelligence recently reviewed the results presented at the American Thoracic Society (ATS) conference held May 18-23, 2012 in San Francisco, CA. The strong competition to launch the next fixed dose combination (FDC) blockbuster for chronic obstructive pulmonary disease (COPD) was of particular interest to reviewer Jennifer Stacey, Citeline's Analyst in Autoimmune/Inflammation.

(Photo: http://photos.prnewswire.com/prnh/20120531/NE16127-INFO )

In the absence of results from GlaxoSmithKline and Theravance's market-leading RELOVAIR program, top COPD trials data presented at the conference include results from Novartis' Phase III NVA237 GLOW2 trial and final Phase II data from Boehringer Ingelheim's olodaterol monotherapy program. Both drugs provided significant improvement in bronchodilation with once-daily dosing, and these studies supported the dose selections for their respective FDC trials. Mid-sized companies Almirall and Forest showed sustained success of their partnered aclidinium bromide drug program, while privately-held Pearl Therapeutics divulged eight clinical publications at ATS, revealing statistically significant efficacy results and future plans for their LAMA/LABA (glycopyrrolate+formoterol fumarate), PT003.

"The presentations at ATS this year provide further evidence of high competition to launch next generation FDC respiratory drugs. COPD has superseded asthma as the lead indication in the market race, most likely due to the FDA's new safety controls pertaining to limited use of all LABA-containing drugs in asthma as well as the unmet need for improved therapies for COPD," states Ms. Stacey, "Additionally, it appears that most companies are strategically conducting trials to launch their novel LAMA or LABA as monotherap
'/>"/>

SOURCE Citeline
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
2. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
3. Study Shows Need to Test More COPD and Asthma Patients for Underdiagnosed Pulmonary Disease
4. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
5. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
6. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
7. Inverseon Announces Positive Phase IIa Asthma Study
8. Study Compares Bronchodilatory Effects of SYMBICORT(R) and Advair in Adults With Asthma
9. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
10. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
11. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ... (OFT) approval condition to the announced tender offer for all of ... As a result of the waiver, the transaction is no longer ... offer on January 24, 2014 following the currently scheduled expiration time, ...
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), through ... of highly sophisticated agro-breeding solutions for plant breeders and ... Company,s board of directors appointed chemistry and pharmaceutical industry ... member of the board. From 1975 to ...
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2
... Pharmaceutical Inc. (Nasdaq: BMRN ) today ... BioMarin, will host a conference call and webcast ... to discuss fourth quarter and full year 2010 ... Number:  617.213.8848Participant Code: 90635895Replay Dial-in Number: 888.286.8010Replay International ...
... Matrixx Initiatives, Inc. (Nasdaq: MTXX ... company that develops and markets Zicam® products, today ... for in the previously announced merger agreement, dated ... Matrixx, Wonder Holdings, Inc. ("Wonder") and Wonder Holdings ...
Cached Medicine Technology:BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results 2Matrixx Initiatives, Inc. Announces End of 'Go-Shop' Period 2Matrixx Initiatives, Inc. Announces End of 'Go-Shop' Period 3
(Date:4/17/2014)... have identified new pain relief targets that could ... BBSRC-funded researchers at King,s College London made the ... in the periphery of the body. , Dr ... identifying mechanisms underlying pain generation and our findings ... side effects." , One potential side effect of ...
(Date:4/17/2014)... to a study published today in PLOS Pathogens ... where malaria is common can mount an immune response ... to avoid repeated bouts of high fever and illness ... their bloodstream. The findings may help researchers develop future ... the malaria parasite. , Each year, approximately 200 million ...
(Date:4/17/2014)... School of Medicine report that older women, plucky individuals ... are more likely to be compassionate toward strangers than ... this month,s issue of the International Journal of ... with better health and well-being as we age, the ... outcomes of individuals whose deficits in compassion put them ...
(Date:4/17/2014)... In a review published in the April issue ... of The Feinstein Institute for Medical Research, says it,s ... community,s approach to treating sepsis, which kills ... , Sepsis occurs when molecules released into the bloodstream ... the body. Inflammation is necessary for maintaining good health ...
(Date:4/17/2014)... has created a new technology for modifying human ... the body and selectively target cancer and other ... that monitor and modify human physiology is a ... existing technology enabled bioengineers to build such devices ... in a customized fashion. , "The project addressed ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:Study sheds light on how the immune system protects children from malaria 2Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2
... New Online Enrollment Center in OnRamp® ,provides centralized access point ... ... (Vocus) May 21, 2009-- Broadlane, the leading cost-management ... enhancement for client convenience - Enrollment Center. This new functionality ...
... 60 Percent of College Seniors Worried They Won,t Land a Job ... Lost a Job This Year, and 1 in 3 College Students ... YORK, May 21 As millions of college students ... college network and The Associated Press today ...
... to Surpass $100 Million Contribution Mark to Support Families Living with ... ... May 21, 2009 -- Safeway (NYSE:SWY) captures Easter ... the organizations, services for children and adults with autism and other ...
... injury rights of bicyclists hit by motor vehicles. , ... New York (PRWEB) May 21, ... and more people are using bicycles to get around the city. Bicyclists need ... , , ,David Perecman, a leading New York personal injury lawyer based ...
... OAK BROOK, Ill., May 21 The University HealthSystem ... 3-year agreement with Mzinga, Inc. for on-demand learning solutions. ... and became effective on March 1, 2009, positions Mzinga ... UHC member hospitals throughout the United States, building on ...
... The following is a statement of Matthew L. ... http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO )The Campaign for Tobacco-Free ... his leadership role in Senate committee approval of ... Administration (FDA) regulatory authority over tobacco products, including ...
Cached Medicine News:Health News:Broadlane Automates Contract Enrollment for Clients 2Health News:Broadlane Automates Contract Enrollment for Clients 3Health News:Broadlane Automates Contract Enrollment for Clients 4Health News:Broadlane Automates Contract Enrollment for Clients 5Health News:New mtvU & Associated Press Poll Shows How Stress, the Economy & Other Factors are Affecting College Students' Mental Health 2Health News:New mtvU & Associated Press Poll Shows How Stress, the Economy & Other Factors are Affecting College Students' Mental Health 3Health News:New mtvU & Associated Press Poll Shows How Stress, the Economy & Other Factors are Affecting College Students' Mental Health 4Health News:New mtvU & Associated Press Poll Shows How Stress, the Economy & Other Factors are Affecting College Students' Mental Health 5Health News:New mtvU & Associated Press Poll Shows How Stress, the Economy & Other Factors are Affecting College Students' Mental Health 6Health News:New mtvU & Associated Press Poll Shows How Stress, the Economy & Other Factors are Affecting College Students' Mental Health 7Health News:Safeway Earns Easter Seals' All-Time Top Corporate Partner Designation 2Health News:Safeway Earns Easter Seals' All-Time Top Corporate Partner Designation 3Health News:Safeway Earns Easter Seals' All-Time Top Corporate Partner Designation 4Health News:New York Personal Injury Lawyer Seeks to Protect Bicyclists From Harm 2Health News:University HealthSystem Consortium Selects Mzinga for On-Demand Learning Services 2Health News:University HealthSystem Consortium Selects Mzinga for On-Demand Learning Services 3Health News:Sen. Jeff Merkley Votes to Protect America's Kids From Tobacco 2Health News:Sen. Jeff Merkley Votes to Protect America's Kids From Tobacco 3
... many as three tests confirmed Sterillium Rub's ... according to FDA (Time Kill study and ... Drug Products) and one European test - ... the relevant international efficacy specifications. Sterillium Rub ...
HIBICLENS' non-drying, low skin irritation potential promotes compliance with the frequent hand washing associated with today's clinical protocols....
... All of The Scrub Care® ... are formulated for the ultimate in ... harmful bacteria while keeping skin healthy ... use. This solutions do not contain ...
Exidine® 2% CHG Brushless Surgical Scrub offers exceptional persistence and broad-spectrum antimicrobial activity....
Medicine Products: